Hepatitis B testing

Hepatitis B testing requires a blood draw — you cannot test with a urine sample or oral swab. The recommended test is the <strong>hepatitis B panel</strong>, which orders three markers simultaneously: HBsAg (surface antigen — detects active infection), anti-HBs (surface antibody — indicates immunity from vaccination or resolved past infection), and anti-HBc (core antibody — indicates any prior exposure to the virus). You can order this panel online at a private lab such as Quest or LabCorp and walk in without an appointment, ask for it at your next routine medical visit, or visit a health department or community health center that may offer it free or at low cost. Results typically return in 1–3 business days. If your result shows active infection, your provider will order additional tests (HBeAg, HBV DNA) to stage the infection and guide treatment decisions.

<strong>HBsAg</strong> (the surface antigen that signals active infection) typically becomes detectable in blood 1–9 weeks after exposure, often before any symptoms appear. However, testing too early in this window can yield a false negative if the antigen has not yet reached detectable levels. Anti-HBc (core antibody) and anti-HBs develop over additional weeks and are part of the full picture that distinguishes acute infection, chronic infection, resolved infection, and vaccine immunity. If you believe you were exposed within the past week, do not wait for a test result — contact a provider immediately to receive post-exposure prophylaxis (HBIG + vaccine), which can prevent infection if given promptly. For a routine screening with no acute exposure, a panel at any point accurately captures your current status.

The three-marker hepatitis B panel tells a complete story, and interpreting all three together is essential. <strong>HBsAg positive, anti-HBs negative:</strong> active hepatitis B infection, either acute or chronic — your provider will determine which based on additional testing and timing. <strong>HBsAg negative, anti-HBs positive (≥10 mIU/mL), anti-HBc negative:</strong> immune from vaccination — no prior infection. <strong>HBsAg negative, anti-HBs positive, anti-HBc positive:</strong> immune from a resolved past infection — you cleared HBV and cannot be reinfected. <strong>HBsAg negative, anti-HBs negative, anti-HBc positive</strong> ('isolated core antibody'): this pattern requires provider interpretation — it can represent a false positive, very remote resolved infection with waned anti-HBs, or rarely occult chronic infection. <strong>All three negative:</strong> susceptible — you have not been infected and are not immune; vaccination is strongly recommended.

Yes — the hepatitis B vaccine is one of the safest and most effective vaccines in use, with more than 90% efficacy in producing protective immunity in healthy adults. Two schedules are available: the <strong>3-dose series</strong> (Engerix-B or Recombivax HB at 0, 1, and 6 months) and the newer <strong>2-dose series</strong> (Heplisav-B, two shots 4 weeks apart, approved for adults 18 and older). The CDC recommends vaccination for all infants starting at birth, all previously unvaccinated children and adolescents, and all adults through age 59. Adults 60 and older should be vaccinated if they want protection or have risk factors such as diabetes, chronic liver or kidney disease, or potential sexual or occupational exposure. If you don't know whether you were vaccinated, a blood test (anti-HBs) can confirm immunity — if you're negative, get vaccinated regardless of age.

Acute hepatitis B refers to the initial infection — the first 6 months after exposure. In approximately 95% of adults with intact immune systems, the immune response clears the virus during this period without any treatment, and the person develops lifelong natural immunity. Chronic hepatitis B is defined as HBsAg persisting in the blood for more than 6 months, meaning the immune system did not fully clear the virus. Fewer than 5% of adults develop chronic HBV, but this proportion rises dramatically with younger age at infection: approximately 25–50% of children infected between ages 1 and 5 develop chronic infection, and more than 90% of neonates infected at birth do so. Chronic HBV passes through distinct phases — immune tolerant (high viral load, minimal liver injury), immune active (inflammation and fibrosis risk), inactive carrier (low viral load, stable liver), and reactivation (resurgence of replication) — each requiring different management decisions.

Acute hepatitis B in a healthy adult resolves on its own in about 95% of cases — the immune system clears the virus and confers lifelong immunity — so it is effectively 'cured' by the immune response. Chronic hepatitis B does not have a conventional cure for most patients: <strong>HBsAg clearance</strong> (called 'functional cure') occurs in only about 1–3% of treated patients per year, though it is the goal of newer investigational therapies. What current treatment does achieve is highly effective suppression: once-daily antivirals (entecavir or tenofovir) drive HBV DNA to undetectable levels, normalize liver enzymes, halt fibrosis progression, and reduce hepatocellular carcinoma risk by approximately 70–80%. For most people with chronic HBV, this means living a full, healthy life with regular monitoring — the condition is well-managed rather than cured. Novel therapeutic strategies including RNA-targeting agents and therapeutic vaccines are in clinical trials aiming at functional cure.

Chronic hepatitis B is treated with once-daily oral antiviral medications, primarily <strong>entecavir</strong> or <strong>tenofovir</strong> (either tenofovir disoproxil fumarate, TDF, or the newer tenofovir alafenamide, TAF). These drugs inhibit the HBV reverse transcriptase enzyme, blocking viral replication and driving HBV DNA to undetectable levels in blood. They are well-tolerated with a low side-effect burden; tenofovir is also a component of standard HIV antiretroviral regimens, which is relevant for HBV/HIV co-infected patients. Treatment is typically lifelong because stopping antivirals in most patients leads to viral rebound and hepatitis flares. Not every person with chronic HBV needs immediate treatment — the decision depends on HBV DNA level, ALT (liver enzyme) activity, phase of infection, degree of liver fibrosis assessed by FibroScan or biopsy, and age. A hepatologist or gastroenterologist manages these decisions and monitors the patient long-term.

If you believe you were exposed to HBV through unprotected sex, a needlestick, a blood splash, or sharing injection equipment, seek care immediately — post-exposure prophylaxis (PEP) is time-sensitive. The standard PEP regimen is <strong>hepatitis B immune globulin (HBIG)</strong> plus the first dose of the hepatitis B vaccine series. HBIG provides immediate passive antibodies that can neutralize circulating virus; the vaccine initiates active immunity. This combination is most effective when given within 12–24 hours of exposure and should not be given more than 7 days after a needlestick or percutaneous exposure, or more than 14 days after a sexual exposure. Do not wait for symptoms or laboratory results before seeking PEP — by the time symptoms appear (if they appear at all), the 24–48 hour optimal window has long passed. Emergency departments and sexual health clinics can provide PEP at any hour.

Perinatal transmission — from an HBsAg-positive mother to her newborn during delivery — is the most common cause of chronic HBV acquisition globally, because neonates infected at birth have a greater than 90% probability of developing chronic infection. The intervention is highly effective: every infant born to an HBsAg-positive mother should receive both <strong>hepatitis B immune globulin (HBIG) and the first dose of the HBV vaccine within 12 hours of birth</strong> — this combination reduces perinatal transmission by more than 90%. All pregnant people are screened for HBsAg at the first prenatal visit precisely to enable this intervention. For mothers with very high viral loads (HBV DNA >200,000 IU/mL), tenofovir started at approximately 28 weeks of pregnancy provides additional protection by reducing the maternal viral load at delivery. These infants complete the full 3-dose vaccine series and are tested at 9–18 months to confirm the outcome.

HBV spreads through direct contact with infected blood and body fluids. The main routes are: unprotected sexual intercourse (vaginal, anal, or oral) with an infected partner; sharing needles, syringes, or other drug-injection equipment; mother-to-child transmission during childbirth; and, less commonly, sharing personal items that may carry traces of blood (razors, toothbrushes). HBV is significantly more infectious than HIV — approximately 50–100 times more so per needlestick — because it can survive on surfaces for at least 7 days and requires a very small inoculum to cause infection. However, HBV is <em>not</em> spread through casual contact. You cannot get HBV by hugging, shaking hands, sharing food or water, coughing, sneezing, or using the same toilet as someone who is infected. Breastfeeding is safe once the newborn has received the birth-dose vaccine and HBIG.

<strong>Yes — HBV is the world's leading cause of liver cancer (hepatocellular carcinoma, HCC)</strong>, responsible for approximately 50% of HCC cases globally. Unlike most other causes of HCC, HBV can cause liver cancer even in the absence of cirrhosis, because HBV DNA integrates into host chromosomes and can directly activate cancer-promoting genes. The risk of HCC is particularly elevated in patients with high viral load, genotype C infection, a family history of HCC, or male sex over age 40. People with cirrhosis from any cause — including HBV — face a 1–4% annual risk of HCC. Regular surveillance with liver ultrasound and alpha-fetoprotein (AFP) every 6 months is standard care for all patients with cirrhosis or qualifying HBV profiles and dramatically improves detection at a treatable stage. Effective antiviral treatment reduces HCC risk by approximately 70–80% but does not eliminate it, so surveillance continues even on treatment.

No. People who clear an acute hepatitis B infection develop robust, durable natural immunity — the immune system generates protective anti-HBs antibodies that prevent reinfection for life. This is fundamentally different from the situation with hepatitis C, which can reinfect after clearance. If a blood test following your recovery shows HBsAg negative and anti-HBs positive with anti-HBc positive, you are immune and protected from reinfection. This natural immunity is clinically equivalent to the immunity produced by the vaccine. The only exception relevant in practice is concurrent infection with the hepatitis D virus (HDV, also called 'delta hepatitis'), which is a defective RNA virus that requires HBV for replication — reinfection with HDV superinfection in a person with chronic HBV is a separate concern but does not apply to someone who has resolved their HBV infection.

Chronic hepatitis B requires lifelong specialist care rather than any single follow-up test. The monitoring framework involves: <strong>HBV DNA (viral load)</strong> every 3–6 months to track viral activity and treatment response; <strong>ALT and AST</strong> liver enzyme testing at the same intervals to assess hepatic inflammation; periodic <strong>liver imaging and elastography</strong> (FibroScan) to stage fibrosis — typically every 1–3 years depending on the phase of infection; <strong>HBeAg and anti-HBe</strong> testing to track e-antigen seroconversion; and <strong>HCC surveillance with ultrasound</strong> every 6 months for all patients with cirrhosis or elevated cancer risk profiles. On antiviral treatment, the goal is HBV DNA suppression to undetectable levels and ALT normalization; these targets are confirmed at each visit. Patients also need monitoring for drug side effects — tenofovir can affect kidney function and bone density, so periodic creatinine and DEXA scans may be warranted for long-term users.

A hepatitis B panel (HBsAg, anti-HBs, anti-HBc) typically costs $30–$100 self-pay at a private laboratory. Most ACA-compliant insurance plans cover HBV screening and the vaccine series with no out-of-pocket cost, consistent with USPSTF preventive service recommendations. Health departments, federally qualified health centers, and many community health centers offer hepatitis B testing and vaccination at no charge or on a sliding-fee scale. If you are uninsured, calling ahead to a local health department or FQHC is often the fastest route to free testing and vaccination.

Yes — HBV and HIV share transmission routes (sexual contact, injection drug use, perinatal), so co-infection is common. People with HIV have higher rates of chronic HBV (approximately 5–10% of HIV-positive individuals in the U.S. have chronic HBV) and experience more rapid progression to cirrhosis and HCC when co-infected. Fortunately, several first-line HIV antiretroviral regimens — specifically those containing tenofovir (TDF or TAF) — are active against both viruses simultaneously, providing dual treatment with a single drug. This means HBV/HIV co-infected patients should be managed by a specialist familiar with both infections, and their antiretroviral regimen should always include a tenofovir-containing backbone. Abrupt discontinuation of antiretrovirals in co-infected patients can cause severe HBV rebound ('hepatitis flare'), so treatment changes require careful planning.